The Role of Biomarkers for Management of Crohn Disease: A Guideline Topline
New clinical practice guidelines on Crohn disease (CD) from the American Gastroenterological Association (AGA) emphasize the value of biomarkers in effectively managing both symptomatic and asymptomatic disease.
The Guidelines Committee points out that although the number of therapeutics with novel mechanisms have increased in the past decade, almost half of patients still require surgery over the course of their illness. That prognosis can be improved, according to the AGA, by earlier administration of effective treatment followed by accurate monitoring to ensure that therapeutic targets are attained.
To improve the accuracy of monitoring and better inform disease management, the AGA provides guidance on utilizing the biomarkers fecal calprotectin and serum C-reactive protein (CRP), and advises when endoscopic evaluation is warranted to ascertain status of disease activity. The following slides offer a topline look at the new guideline.
The Value of Biomarkers in Management of Crohn Disease
Crohn Disease: Symptom-Based vs Biomarker-Based Monitoring
Biomarkers Not Specific for Crohn Disease
Biomarker Assessment in Crohn Disease May Have Limited Accuracy in Small Bowel, Upper GI Disease
Crohn Disease: Qualifications for use of Biomarkers in Disease Management
CRP, Fecal Calprotectin Tests May Deliver Variable Results for Crohn Disease
Biomarker Interpretation in Small Bowel Crohn Disease
Fecal Calprotectin and CRP Cut-off Values for Ruling Out Inflammation in Crohn Disease
Strategy When Biomarkers are Elevated in Crohn Disease with Symptomatic Remission
Using Interval Biomarker-Based Assessment and Treatment Adjustment for Symptomatic Crohn Disease
Strategy when Biomarkers are Within Normal Limits but Patient is Symptomatic
Use of CRP, Fecal Calprotectin in Post-Op Management of CD with Low Risk of Symptom Recurrence
